A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-067
- Sponsors Bristol-Myers Squibb
- 05 Jul 2024 This study has been completed in Sweden, according to European Clinical Trials Database record.
- 02 Jul 2024 Status changed from active, no longer recruiting to completed.
- 27 Jun 2024 This study has been completed in Denmark, according to European Clinical Trials Database record.